<DOC>
	<DOCNO>NCT02487602</DOCNO>
	<brief_summary>The purpose study evaluate gastrointestinal behaviour novel weight loss device vivo understand device 's mechanism action aid weight loss .</brief_summary>
	<brief_title>A Scintigraphic Study Investigate Effect Gelesis100 Gastric Emptying Overweight Obese Subjects</brief_title>
	<detailed_description>Gelesis100 new , experimental medical device develop Gelesis , Inc. aid weight loss overweight/obese patient reduce amount food require make feel full . The device contain capsule swallow water meal . Once swallow , capsule dissolve capsule content hydrate mix food stomach , create feel fullness . Four different treatment 5 capsule give participant study . These mixture Gelesis100 capsule capsule contain device i.e. , placebo ( contain sucrose [ sugar ] ) The study design look : - The time take stomach empty receive treatment - The time take food Gelesis100 travel intestine - The effect Gelesis100 feel satiety ( full participant feel ) In order monitor gastrointestinal behavior , either small amount radioactive material add component standard lunch water give treatment . The radiation emit detected travel GI tract take image use device know gamma camera . The procedure relatively easy non- invasive .</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<criteria>1 . Weight &amp; Body mass index ( BMI ) 1 . BMI 27 35 kg/m² , inclusive . 2 . Body weight ≥50 kg 2 . Compliance : Understands willing , able likely comply study procedure restriction . 3 . Consent : Demonstrates understand study willingness participate evidence voluntary write informed consent ( sign date ) obtain trialrelated activity . Trialrelated activity procedure would perform normal management subject . 4 . General health : Good general health ( opinion Investigator ) clinically significant relevant abnormality medical history physical examination . 1 . Medical History 1 . Current recurrent disease , opinion physician responsible , could affect study conduct laboratory assessment ( e.g. , hepatic disorder , renal insufficiency , congestive heart failure ) . 2 . Current relevant previous history serious , severe unstable physical psychiatric illness , medical disorder may require treatment make subject unlikely fully complete study , condition present undue risk study medication procedure . 3 . A history current relevant previous non selflimiting GI disorder . 4 . A history gastric bypass gastric surgery . 5 . Acute diarrhoea constipation 14 day assessment visit . Diarrhoea define passage liquid faeces and/or stool frequency great 3 time per day . Constipation define failure open bowel least every day . 6 . Currently suffer disease know impact gastric emptying , e.g. , migraine , type 1 type 2 diabetes . 7 . As result physical examination screen investigation , physician responsible considers volunteer unfit study . 2 . Medications 1 . Subject take prescribed medication within 14 day prior first assessment visit . Subjects withdraw subsequent study day commence take prescribed medication study period . 2 . Subject take overthecounter ( OTC ) medication within 48 hr prior assessment visit . This include use vitamin natural herbal remedy e.g. , St John 's Wort . 3 . Subject take OTC and/or prescribe NonSteroidal AntiInflammatory Drugs ( NSAIDS ) daily regularly within 3 month prior first assessment visit . Subjects withdraw subsequent study day commence take OTC and/or prescribe NSAIDS study period . 3 . Alcohol/Substance Abuse 1 . Recent history ( within last year ) alcohol substance abuse . 2 . Subject average weekly alcohol intake great 21 unit . 1 unit equivalent one 25 mL single measure whisky , third pint beer half standard ( 175 mL ) glass red wine . 3 . Subject positive urine drug abuse test screening . 4 . Subject positive breath alcohol test screening . 4 . Smoking 1 . Subject recently discontinue smoking ( le 6 month ) . 2 . Subject currently smoker user nicotinecontaining product . 5 . Allergy/Intolerance 1 . Subject history allergy drug , component dosage form allergy , , opinion physician responsible , contraindicate participation . 2 . Has allergy content standardize breakfast lunch . 3 . Subject vegetarian . 4 . Subject lactose intolerant . 6 . Clinical Studies 1 . Participation another clinical study ( inclusive final poststudy examination ) receipt investigational drug within 12 week first screen visit . 2 . Previous participation study . 3 . Subject whose participation study result participation four study 12month period . 7 . Personnel . An employee sponsor , client study site member immediate family . 8 . Radiation Exposure 1 . Subjects participation study exceed limit total radiation exposure allow 12month period ( 5 mSv ) , exceed 10 mSv threeyear period . 2 . Subjects intend father child 3 month follow study unwilling abstain sexual intercourse pregnant lactating woman . 3 . Subjects unwilling use condom/spermicide addition female partner use another form contraception IUD , diaphragm spermicide , oral contraceptive , injectable progesterone , subdermal implant tubal ligation woman could become pregnant time assessment visit 3 month follow study . 9 . Blood . Subject donate blood experienced significant blood loss within 3 month screen duration study . 10 . Other . Subject nonremovable metal object metal plate , screw etc chest abdominal area .</criteria>
	<gender>Male</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>